HCWB
HCW Biologics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.57M
P/E Ratio
—
EPS
$-10.63
Beta
0.79
52W High
$11.22
52W Low
$0.25
50-Day MA
$0.72
200-Day MA
$2.75
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About HCW Biologics Inc
HCW Biologics Inc is an innovative biotechnology firm at the forefront of developing novel immunotherapies and vaccine technologies targeting critical health challenges, including cancer and infectious diseases. Utilizing proprietary platforms that unlock the potential of the immune system, the company aims to deliver transformative biopharmaceutical solutions. With a robust pipeline of clinical candidates and strategic collaborations, HCW Biologics is well-positioned to drive advancements in patient care while addressing significant unmet medical needs, making it an attractive investment prospect for institutional investors in the growing biotechnology landscape.
Fundamentals
| Revenue (TTM) | 54,230 |
| Gross Profit (TTM) | 10,850 |
| EBITDA | $-10.62M |
| Operating Margin | -10966.00% |
| Return on Equity | -27726.00% |
| Return on Assets | -26.60% |
| Revenue/Share (TTM) | $0.03 |
| Book Value | $-0.80 |
| Price-to-Book | 0.34 |
| Price-to-Sales (TTM) | 28.98 |
| EV/Revenue | 106.93 |
| EV/EBITDA | -3.63 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -93.20% |
| Shares Outstanding | $3.52M |
| Float | $5.99M |
| % Insiders | 8.60% |
| % Institutions | 6.78% |
Data last updated: 4/8/2026